About Us
Pipeline
The Science
Newsroom
Publications
Investor Relations
Patient Resources

From the Lab

Email Alerts

bg-ad-amnestic-mild-cognitive-impairment

Email Alerts

Stay up to date on the latest AgeneBio news.

Recent Posts

Recent Report That Levetiracetam Could Stop the Plaque Formation of Alzheimer’s Disease in Its Earliest Stages Is Further Confirmation of The Positive Effects of AgeneBio’s Novel Therapeutic Approach to Treating Alzheimer’s Disease
The Alzheimer’s Association International Conference (AAIC) Toronto July 27-31 2025
Medical News Today: Could a once-daily pill for seizures also treat Alzheimer’s disease?
AgeneBio’s Phase 2B Trial Shows AGB101 Slows Progression of Brain Atrophy in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Who Are Non-Carriers of the APoE-4 Allele
AgeneBio Founder Michela Gallagher Presents Hope4MCI Results at 12th Alzheimer’s & Parkinson’s Drug Development Summit

Recent Comments

millpettata1985 on Home
Digital Profit on Home

Archives

Categories

Events
In the News
Recent News

Meta

Log in
Entries feed
Comments feed
WordPress.org

AgeneBio, Inc.
1340 Smith Avenue, Suite 200
Baltimore, MD 21209

P: 410.779.1260

Privacy Policy
Terms of Use

©2026 AgeneBio, Inc. All rights reserved.

Quick Links

About Us
Pipeline
The Science
Newsroom
Publications
Investor Relations
Patient Resources

Privacy Policy
Terms of Use

©2026 AgeneBio, Inc. All rights reserved.

Top